Agenus (NASDAQ: AGEN) reported Q1 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $12.35 million.

"We accelerated the development of AGEN1181, advanced our plans to file our BLAs and filed two INDs for our allogeneic iNKT cell therapy to treat cancer and COVID-19," said Garo Armen, Ph.D., Chairman and CEO, Agenus. "Our ability to rapidly enroll in our bali and zali trials, in just 2 years, underscores the speed with which we can advance our AGEN1181 +/- bali and our innovative pipeline of products including allogeneic cell therapy programs."

For earnings history and earnings-related data on Agenus (AGEN) click here.